Standardized SEC financial data for USANA HEALTH SCIENCES INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000896264 · NYSE · Medicinal Chemicals & Botanical Products.
Ratios for fiscal year 2026, standardized from SEC filings.
| USD | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $1.13B | $1.19B | $998.6M | $921.0M | $854.5M | $925.3M |
| Cost of revenue | $209.1M | $217.9M | $193.9M | $176.7M | $161.2M | $200.9M |
| Gross profit | $925.5M | $968.6M | $804.7M | $744.3M |
| USD | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $315.9M | $243.7M | $291.3M | $333.2M | $184.5M | $161.2M |
| Inventory | $90.2M | $98.3M | $67.1M | $61.5M | $69.7M | $102.6M |
| Total current assets | $425.3M | $365.1M | $384.4M | $417.7M |
| USD | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Operating cash flow | $160.4M | $121.2M | $103.9M | $70.6M | $61.0M | $22.3M |
| Capital expenditures | $15.1M | $12.8M | $10.4M | $14.5M | $10.1M | $13.8M |
| Free cash flow | $145.3M | $108.5M | $93.5M | $56.1M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/USNA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/USNA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $693.3M |
| $724.4M |
| R&D expense | $10.6M | $11.1M | $11.6M | $11.4M | $11.6M | $10.7M |
| SG&A expense | $261.2M | $279.1M | $262.3M | $257.0M | $263.3M | $337.4M |
| Operating income | $176.5M | $170.2M | $107.6M | $93.1M | $66.3M | $37.4M |
| EBITDA | $190.2M | $183.2M | $121.0M | $105.8M | $80.9M | $70.0M |
| Interest expense | $711K | $57K | $192K | $262K | $76K | $663K |
| Pretax income | $177.9M | $170.6M | $108.6M | $102.5M | $76.4M | $41.5M |
| Income tax | $53.3M | $54.1M | $39.3M | $38.7M | $34.3M | $30.1M |
| Net income | $124.7M | $116.5M | $69.3M | $63.8M | $42.0M | $10.8M |
| EPS (diluted) | $5.86 | $5.73 | $3.59 | $3.30 | $2.19 | $0.58 |
Standardized from USANA HEALTH SCIENCES INC's SEC filings — per-share figures split-adjusted. Full history via the API.
| $279.2M |
| $288.4M |
| Property, plant & equipment | $100.4M | $101.8M | $97.8M | $99.8M | $94.6M | $94.4M |
| Goodwill | $17.4M | $17.7M | $17.4M | $17.1M | $144.2M | $138.0M |
| Total assets | $640.9M | $577.7M | $596.5M | $632.8M | $748.2M | $742.9M |
| Total current liabilities | $168.1M | $160.8M | $143.8M | $118.8M | $139.6M | $128.6M |
| Total liabilities | $199.2M | $182.6M | $162.1M | $135.6M | $216.1M | $209.8M |
| Retained earnings | $382.8M | $344.6M | $391.6M | $445.2M | $478.9M | $465.7M |
| Total equity | $441.6M | $395.1M | $434.5M | $497.2M | $532.1M | $533.1M |
| $50.9M |
| $8.5M |
| Investing cash flow | -$34.0M | -$14.2M | -$12.4M | -$12.0M | -$213.1M | -$10.1M |
| Financing cash flow | -$59.4M | -$181.4M | -$30.1M | -$14.2M | $9.6M | -$40.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | $57.0M | $177.8M | $25.4M | $11.6M | $9.4M | $27.5M |